Rohit K Jain
Overview
Explore the profile of Rohit K Jain including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
849
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sweis R, Chatta G, Jain R, Moon H, Delacroix S, Fang A, et al.
Clin Cancer Res
. 2024 Nov;
31(2):299-307.
PMID: 39576210
Purpose: Advanced urothelial cancer generally has high mortality despite modern anti-PD-1/L1 antibody-based combinations. Augmenting checkpoint inhibitor-mediated immune responses with lymphocyte growth factors may improve outcomes. We conducted a randomized phase...
2.
Li R, Villa N, Yu X, Johnson J, Borjas G, Dhillon J, et al.
Nat Med
. 2024 Nov;
31(1):176-188.
PMID: 39521884
There is a critical unmet need for safe and efficacious neoadjuvant treatment for cisplatin-ineligible patients with muscle-invasive bladder cancer. Here we launched a phase 1b study using the combination of...
3.
Liveringhouse C, Sim A, Zhang J, Jain R, Naidu S, Linkowski L, et al.
Clin Genitourin Cancer
. 2024 Oct;
22(6):102222.
PMID: 39353214
Background: Neuroendocrine carcinoma of the bladder (NEC-bladder) is a rare disease with poor outcomes and variable treatment approaches. Materials And Methods: Patients with localized NEC-bladder treated with surgery or radiation...
4.
Petrylak D, Tagawa S, Jain R, Bupathi M, Balar A, Kalebasty A, et al.
J Clin Oncol
. 2024 Aug;
42(29):3410-3420.
PMID: 39186707
Purpose: Sacituzumab govitecan (SG) is a Trop-2-directed antibody-drug conjugate with an SN-38 payload, approved for patients with locally advanced (LA) or metastatic urothelial cancer (mUC) who progressed after platinum (PT)-based...
5.
Loriot Y, Balar A, Petrylak D, Kalebasty A, Grivas P, Flechon A, et al.
Clin Cancer Res
. 2024 Aug;
30(15):3179-3188.
PMID: 39086310
Purpose: Human trophoblast cell surface antigen 2 (Trop-2) is a protein highly expressed in urothelial cancer (UC). Sacituzumab govitecan (SG) is a Trop-2-directed antibody drug conjugate with a hydrolysable linker...
6.
Skelton 4th W, Masur J, Thomas J, Fallah P, Jain R, Ravi P, et al.
Clin Genitourin Cancer
. 2024 Jul;
22(5):102143.
PMID: 39032202
Introduction: The renin-angiotensin system (RAS) has been demonstrated to modulate cell proliferation, desmoplasia, angiogenesis and immunosuppression. We examined the association of RAS inhibitors (RASi)-namely angiotensin converting enzyme inhibitors (ACEi) and...
7.
Kohlmann W, Nix D, Pauley K, Greenberg S, Atkinson A, Boucher K, et al.
JCO Precis Oncol
. 2024 Jul;
8:e2300697.
PMID: 38976819
Purpose: This study investigates a real-world multicenter cohort of patients with urinary tract cancer (UTC), with primary disease sites including the bladder, urethra, and upper tract, who enrolled for research...
8.
Loriot Y, Kalebasty A, Flechon A, Jain R, Gupta S, Bupathi M, et al.
Future Oncol
. 2024 Apr;
20(23):1621-1631.
PMID: 38682560
What Is This Summary About?: Sacituzumab govitecan (brand name: TRODELVY) is a new treatment being studied for people with a type of bladder cancer, called urothelial cancer, that has progressed...
9.
Grivas P, Koshkin V, Chu X, Cole S, Jain R, Dreicer R, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):914-922.
PMID: 38155060
Background And Objective: Neoadjuvant cisplatin-based chemotherapy prior to radical cystectomy (RC) improves overall survival (OS) in muscle-invasive bladder cancer (MIBC). However, many patients are cisplatin ineligible; therefore, new treatment options...
10.
Li R, Naidu S, Fan W, Rose K, Huelster H, Grass G, et al.
Urol Oncol
. 2023 Oct;
41(11):457.e17-457.e24.
PMID: 37880002
Background: Despite abundant evidence supporting the use of perioperative chemotherapy from clinical trials, no study to date has comprehensively evaluated its use in the treatment of muscle-invasive bladder cancer (MIBC)...